Synergistic skin heat shock protein expression in response to combined laser treatment with a diode laser and ablative fractional lasers

Figures & data

Table 1. Expression levels of Hsp70 given as median–maximum (rating of staining intensity as follows: 0 = undetected, 1 = low density, 2 = medium density, 3 = dense to 4 = very dense). Ten repetitions investigated on day 3 result in 40 samples per intervention.

	n	Day 0	Day 1	Day 3	Day 6
Neat	40	0–1	0–1	0–1	0–1
Diode	40	0–1	1–2	2.5–3	2–4
AFXL CO2	40	0–1	1–2	3–3	3–4
AFXL Er:YAG	40	0–1	1–3	3–4	3–4
Diode + AFXL CO2	40	1–3	2–3	3–4	4–4
Diode + AFXL Er:YAG	40	0–0	1–3	3–3	4–4
Total samples	240

Figure 1. Hsp70 immunoreactivity in response to various treatment modalities (1) control, no treatment, (2) diode laser treatment only, (3) AFXL using the fractional CO₂ laser (AFXL CO₂, EXELO₂, spot size: 250 μm, 10.600 nm), (4) AFXL using the fractional Er:YAG laser (AFXL Er:YAG, Burane FXL, optic array FX12, 2.940 nm), (5) diode laser treatment prior to AFXL with either CO₂ or (6) the Er:YAG laser at day 0 (directly after intervention), day 1 (1 day after intervention), day 3 (3 days after intervention), and day 7 (7 days after intervention). The expression densities of Hsp70 in skin explants were scored using the following scale: 0 = undetected, 1 = low density, 2 = medium density, 3 = dense or 4 = very dense (e.g. day 6 diode + AFXL Er:YAG).

Figure 2. Box-plot (mean (middle point) ± SE (Box)/SD (Whisker)) of Hsp70 immunoreactivity (rating of staining intensity as follows: 0 = undetected, 1 = low density, 2 = medium density, 3 = dense to 4 = very dense) in response to various treatment modalities (control = no treatment, diode = diode laser treatment, AFXL = ablative fractional laser treatment using either the fractional CO₂ laser (AFXL CO₂, EXELO₂, spot size: 250 μm, 10.600 nm), or the fractional Er:YAG laser (AFXL Er:YAG, Burane FXL, optic array FX12, 2.940 nm).